Servier Expands Its Immuno-Oncology Presence With Sorrento PD-1 Deal
Servier SA has moved to broaden its immune-oncology pipeline by signing a license and collaboration agreement for the development, manufacture and commercialization of products using Sorrento Therapeutics Inc.'s anti-PD-1 monoclonal antibody (mAb) STI-A1110, adding to its ongoing CAR-T efforts.
You may also be interested in...
In Q3, biopharma financing totaled $7.4 billion, a large proportion of which was by rare disease developers; among the highlights in the $23 billion in M&As was Allergan's buying spree, including two NASH companies. Just over $20 billion went into biopharma alliance dealmaking, and neurology assets attracted many of the dollars.
Two of the VC's biotechs merged to create an immuno-microbiome company, while Seres is working with Emulate on better tech for microbiome research. UK specialty pharma Martindale acquired small hospital products-focused UK firm Viridian, and Bayer and X-Chem expanded their drug discovery alliance.
Servier has signed a strategic collaboration agreement with Cellectis to develop and commercialize up to six cancer products in a deal potentially worth $850m.